TrialArthritis & rheumatology (Hoboken, N.J.)2019

Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger.

Paul A Brogan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.